Cargando…
Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients
BACKGROUND: The colorectal cancer antigen GUCY2C exhibits unique split tolerance, evoking antigen-specific CD8(+), but not CD4(+), T-cell responses that deliver anti-tumor immunity without autoimmunity in mice. Here, the cancer vaccine Ad5-GUCY2C-PADRE was evaluated in a first-in-man phase I clinica...
Autores principales: | Snook, Adam E., Baybutt, Trevor R., Xiang, Bo, Abraham, Tara S., Flickinger, John C., Hyslop, Terry, Zhan, Tingting, Kraft, Walter K., Sato, Takami, Waldman, Scott A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477737/ https://www.ncbi.nlm.nih.gov/pubmed/31010434 http://dx.doi.org/10.1186/s40425-019-0576-2 |
Ejemplares similares
-
A Phase I study of AD5-GUCY2C-PADRE in stage I and II colon cancer patients
por: Snook, Adam, et al.
Publicado: (2015) -
GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity
por: Magee, Michael S., et al.
Publicado: (2016) -
Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity
por: Flickinger Jr, John C, et al.
Publicado: (2020) -
GUCY2C at the intersection of obesity and colorectal cancer
por: Waldman, Scott A, et al.
Publicado: (2013) -
Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy
por: Flickinger, John C., et al.
Publicado: (2022)